For the quarter ending 2025-09-30, PAVM made $7,549,000 in revenue. -$6,328,000 in net income. Net profit margin of -83.83%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Less deemed dividend on subsidiary preferred stock attributable to the noncontrolling interests | 0 | 0 | - | 1,874,000 |
| Provision for income taxes | 0 | 0 | - | 0 |
| Revenue | 5,000 | 6,000 | 8,000 | 510,000 |
| Amortization of acquired intangible assets | 0 | 0 | - | 186,000 |
| Sales and marketing | 201,000 | 220,000 | 247,000 | 2,232,500 |
| General and administrative | 3,505,000 | 3,670,000 | 4,384,000 | 5,433,000 |
| Research and development | 1,088,000 | 790,000 | 787,000 | 1,374,500 |
| Cost of revenue | 55,000 | 41,000 | 36,000 | 896,500 |
| Total operating expenses | 4,849,000 | 4,721,000 | 5,454,000 | 10,122,500 |
| Operating loss | -4,844,000 | -4,715,000 | -5,446,000 | -9,612,500 |
| Gain on deconsolidation of subsidiary | 0 | - | - | 0 |
| Debt extinguishments loss - senior secured convertible notes | 0 | 0 | -58,000 | -184,500 |
| Debt modification expense | 0 | 0 | - | -500,000 |
| Interest income | 10,000 | 8,000 | 8,000 | 37,000 |
| Interest expense | 8,000 | 4,000 | 4,000 | 11,000 |
| Change in fair value - equity method investment | -4,382,000 | -10,643,000 | 21,004,000 | 41,666.667 |
| Change in fair value - senior secured convertible notes | 100,000 | 200,000 | 49,000 | -394,000 |
| Management fee income | 3,150,000 | 3,150,000 | 3,150,000 | 1,050,000 |
| Grant income | 163,000 | 80,000 | 18,000 | 100,333.333 |
| Other income (expense), net | -1,167,000 | -7,609,000 | 24,069,000 | 927,500 |
| Income (loss) before provision for income tax | -6,011,000 | -12,324,000 | 18,623,000 | -8,685,000 |
| Net income (loss) before noncontrolling interests | -6,011,000 | -12,324,000 | 18,623,000 | -8,685,000 |
| Net loss attributable to the noncontrolling interests | -628,000 | -403,000 | -345,000 | -1,794,500 |
| Net income (loss) attributable to pavmed inc | -5,383,000 | -11,921,000 | 18,968,000 | -6,890,500 |
| Less series b convertible preferred stock dividends earned | 90,000 | 88,000 | 86,000 | 82,500 |
| Less series c convertible preferred stock dividends earned | 470,000 | 481,000 | 398,000 | - |
| Less deemed dividend on series c convertible preferred stock | -385,000 | -818,000 | -789,000 | - |
| Net income (loss) attributable to pavmed inc. common stockholders | -6,328,000 | -13,308,000 | 17,695,000 | -10,721,000 |
| Net income (loss) per share attributable to pavmed inc. common stockholders basic | -0.29 | -0.74 | 1.28 | -1.043 |
| Net income (loss) per share attributable to pavmed inc. common stockholders diluted | -0.29 | -0.74 | 0.34 | 0.125 |
| Weighted average common shares outstanding, basic | 21,554,546 | 18,084,653 | 13,876,165 | -4,742,999.5 |
| Weighted average common shares outstanding, diluted | 21,554,546 | 18,084,653 | 52,496,401 | 5,831,583 |
PAVmed Inc. (PAVM)
PAVmed Inc. (PAVM)